Intensity Therapeutics, Inc. SEC filings INTS
Intensity Therapeutics, Inc. has 246 filings in SEC EDGAR's recent list, going back to Jan 18, 2013. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Apr 24, 2025 | — |
| CORRESP | Letter to the SEC | Apr 22, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 2, 2025 | — |
| DRS | Filing | Mar 28, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 21, 2025 | — |
| CORRESP | Letter to the SEC | Jan 7, 2025 | — |
| UPLOAD | Letter from the SEC | Dec 26, 2024 | — |
| EFFECT | Filing | Dec 19, 2024 | — |
| CORRESP | Letter to the SEC | Dec 17, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 17, 2024 | — |
| D | Filing | Dec 5, 2024 | — |
| EFFECT | Filing | Jul 11, 2024 | — |
| EFFECT | Filing | Jul 11, 2024 | — |
| CORRESP | Letter to the SEC | Jul 9, 2024 | — |
| CORRESP | Letter to the SEC | Jul 9, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 8, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 8, 2024 | — |
| CERT | Filing | Jun 30, 2023 | — |
| SEC STAFF LETTER | Filing | Jun 29, 2023 | — |
| EFFECT | Filing | Jun 29, 2023 | — |
| CORRESP | Letter to the SEC | Jun 27, 2023 | — |
| CORRESP | Letter to the SEC | Jun 27, 2023 | — |
| CORRESP | Letter to the SEC | Jun 9, 2023 | — |
| UPLOAD | Letter from the SEC | Jun 7, 2023 | — |
| CORRESP | Letter to the SEC | Feb 14, 2023 | — |
| CORRESP | Letter to the SEC | Feb 14, 2023 | — |
| CORRESP | Letter to the SEC | Feb 9, 2023 | — |
| CORRESP | Letter to the SEC | Feb 9, 2023 | — |
| CORRESP | Letter to the SEC | Feb 8, 2023 | — |
| CORRESP | Letter to the SEC | Feb 8, 2023 | — |
| CORRESP | Letter to the SEC | Feb 6, 2023 | — |
| CORRESP | Letter to the SEC | Feb 6, 2023 | — |
| CORRESP | Letter to the SEC | Jan 27, 2023 | — |
| UPLOAD | Letter from the SEC | Jan 23, 2023 | — |
| CORRESP | Letter to the SEC | Nov 9, 2022 | — |
| CORRESP | Letter to the SEC | Nov 9, 2022 | — |
| CORRESP | Letter to the SEC | Nov 3, 2022 | — |
| CORRESP | Letter to the SEC | Nov 3, 2022 | — |
| CORRESP | Letter to the SEC | Nov 2, 2022 | — |
| UPLOAD | Letter from the SEC | Oct 31, 2022 | — |
| SEC STAFF LETTER | Filing | Oct 18, 2022 | — |
| CORRESP | Letter to the SEC | Oct 13, 2022 | — |
| CORRESP | Letter to the SEC | Oct 13, 2022 | — |
| CORRESP | Letter to the SEC | Oct 13, 2022 | — |
| CORRESP | Letter to the SEC | Oct 13, 2022 | — |
| SEC STAFF LETTER | Filing | Oct 13, 2022 | — |
| CORRESP | Letter to the SEC | Oct 11, 2022 | — |
| CORRESP | Letter to the SEC | Oct 11, 2022 | — |
| CORRESP | Letter to the SEC | Oct 3, 2022 | — |
| UPLOAD | Letter from the SEC | Sep 29, 2022 | — |
| CORRESP | Letter to the SEC | May 16, 2022 | — |
| UPLOAD | Letter from the SEC | Apr 28, 2022 | — |
| SEC STAFF LETTER | Filing | Apr 26, 2022 | — |
| CORRESP | Letter to the SEC | Dec 10, 2021 | — |
| CORRESP | Letter to the SEC | Dec 10, 2021 | — |
| CORRESP | Letter to the SEC | Dec 9, 2021 | — |
| UPLOAD | Letter from the SEC | Dec 9, 2021 | — |
| CORRESP | Letter to the SEC | Dec 7, 2021 | — |
| CORRESP | Letter to the SEC | Dec 7, 2021 | — |
| 8-A12B/A | Amendment no. 1 to form 8-a12b | Dec 2, 2021 | — |
| 8-A12B | For registration of certain classes | Nov 30, 2021 | — |
| CORRESP | Letter to the SEC | Nov 18, 2021 | — |
| UPLOAD | Letter from the SEC | Nov 16, 2021 | — |
| CORRESP | Letter to the SEC | Nov 12, 2021 | — |
| UPLOAD | Letter from the SEC | Nov 9, 2021 | — |
| SEC STAFF LETTER | Filing | Nov 8, 2021 | — |
| CORRESP | Letter to the SEC | Oct 28, 2021 | — |
| UPLOAD | Letter from the SEC | Oct 18, 2021 | — |
| DRS | Filing | Sep 20, 2021 | — |
| D | Filing | Jun 12, 2015 | — |
| D/A | Filing | Dec 2, 2014 | — |
| D/A | Filing | Feb 11, 2014 | — |
| D | Filing | Jan 18, 2013 | — |
Showing 73 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- INTS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Shelton, CT
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1567264
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.